United Therapeutics is expected to report higher earnings and revenue for the quarter ended June 2026. The consensus estimate calls for earnings of $6.83 per share, a 6.6% increase from a year ago, on revenue of $804.28 million, up 0.7%. The Zacks Earnings ESP of +1.70% and a Zacks Rank of #3 suggest the company is likely to beat the consensus EPS estimate. In the prior quarter, United Therapeutics posted earnings of $5.82 per share, missing the $6.73 estimate by 13.52%, though it has beaten estimates in two of the last four quarters.
United Therapeutics CorporationExpected higher Q2 earnings and revenue, with positive earnings ESP suggesting a likely beat.